DK0991761T3 - Hidtil ukendte mutaner af gramnegative mucosale bakterier og anvendelse deraf i vacciner - Google Patents
Hidtil ukendte mutaner af gramnegative mucosale bakterier og anvendelse deraf i vaccinerInfo
- Publication number
- DK0991761T3 DK0991761T3 DK97936881T DK97936881T DK0991761T3 DK 0991761 T3 DK0991761 T3 DK 0991761T3 DK 97936881 T DK97936881 T DK 97936881T DK 97936881 T DK97936881 T DK 97936881T DK 0991761 T3 DK0991761 T3 DK 0991761T3
- Authority
- DK
- Denmark
- Prior art keywords
- meningitidis
- lps
- bacteria
- mutants
- deficient
- Prior art date
Links
- 241000894006 Bacteria Species 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 239000002158 endotoxin Substances 0.000 abstract 3
- 229920006008 lipopolysaccharide Polymers 0.000 abstract 3
- 241000588650 Neisseria meningitidis Species 0.000 abstract 2
- 230000002950 deficient Effects 0.000 abstract 2
- 101150041203 lpxA gene Proteins 0.000 abstract 2
- 239000012528 membrane Substances 0.000 abstract 2
- 101710164702 Major outer membrane protein Proteins 0.000 abstract 1
- 101710116435 Outer membrane protein Proteins 0.000 abstract 1
- 230000008436 biogenesis Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000003833 cell viability Effects 0.000 abstract 1
- 238000002649 immunization Methods 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/NL1997/000474 WO1999010497A1 (en) | 1997-08-21 | 1997-08-21 | Novel mutants of gram negative mucosal bacteria and application thereof in vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0991761T3 true DK0991761T3 (da) | 2008-05-19 |
Family
ID=19866207
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK97936881T DK0991761T3 (da) | 1997-08-21 | 1997-08-21 | Hidtil ukendte mutaner af gramnegative mucosale bakterier og anvendelse deraf i vacciner |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7011836B1 (da) |
| EP (1) | EP0991761B1 (da) |
| JP (1) | JP2001514001A (da) |
| AT (1) | ATE384130T1 (da) |
| AU (1) | AU755462B2 (da) |
| CA (1) | CA2300854C (da) |
| DE (1) | DE69738472T2 (da) |
| DK (1) | DK0991761T3 (da) |
| ES (1) | ES2301181T3 (da) |
| NO (1) | NO326858B1 (da) |
| PT (1) | PT991761E (da) |
| WO (1) | WO1999010497A1 (da) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9918319D0 (en) * | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
| ATE394490T1 (de) * | 2000-03-02 | 2008-05-15 | Cp Kelco Us Inc | Mutante bakteriestämme vom genus sphingonomas die defizient in der herstellung von polyhydroxybutyrate sind, und verfahren zur klärung von sphinganen |
| GB0220194D0 (en) | 2002-08-30 | 2002-10-09 | Chiron Spa | Improved vesicles |
| EP1654364A4 (en) * | 2003-08-13 | 2008-02-13 | Novartis Vaccines & Diagnostic | CURRENT HOST CELL RELEASE COMPRISING POLYNUCLEOTIDES ENCODING IMMUNOGENS |
| EP1706481A2 (en) * | 2003-12-23 | 2006-10-04 | GlaxoSmithKline Biologicals S.A. | Vaccine |
| WO2006085910A2 (en) * | 2004-06-04 | 2006-08-17 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Endotoxin-free moraxella catarrhalis |
| GB0424092D0 (en) | 2004-10-29 | 2004-12-01 | Chiron Srl | Immunogenic bacterial vesicles with outer membrane proteins |
| PT1984021T (pt) * | 2006-01-19 | 2016-11-02 | Res Corp Tech Inc | Bactérias gram-negativas não tóxicas viáveis |
| GB0700562D0 (en) | 2007-01-11 | 2007-02-21 | Novartis Vaccines & Diagnostic | Modified Saccharides |
| WO2009050586A1 (en) | 2007-10-19 | 2009-04-23 | Novartis Ag | Meningococcal vaccine formulations |
| CN102356089B (zh) | 2008-02-21 | 2014-02-19 | 诺华股份有限公司 | 脑膜炎球菌fHBP多肽 |
| PT2268618E (pt) | 2008-03-03 | 2015-10-12 | Novartis Ag | Compostos e composições moduladores da actividade tlr |
| JP2012512240A (ja) | 2008-12-17 | 2012-05-31 | ノバルティス アーゲー | ヘモグロビン受容体を含む髄膜炎菌ワクチン |
| CA2765112A1 (en) | 2009-06-10 | 2010-12-16 | Novartis Ag | Benzonaphthyridine-containing vaccines |
| US20110076300A1 (en) | 2009-08-27 | 2011-03-31 | Mariagrazia Pizza | Hybrid Polypeptides Including Meningococcal fHBP Sequences |
| CN102740882A (zh) | 2009-08-27 | 2012-10-17 | 诺华有限公司 | 含有铝、寡核苷酸和聚阳离子的佐剂 |
| ES2443952T3 (es) | 2009-09-02 | 2014-02-21 | Novartis Ag | Composiciones inmunógenas que incluyen moduladores de la actividad de TLR |
| JO3257B1 (ar) | 2009-09-02 | 2018-09-16 | Novartis Ag | مركبات وتركيبات كمعدلات لفاعلية tlr |
| CN102724988B (zh) | 2009-09-30 | 2014-09-10 | 诺华股份有限公司 | 脑膜炎球菌fHBP多肽的表达 |
| CA2779816A1 (en) | 2009-10-27 | 2011-05-05 | Novartis Ag | Modified meningococcal fhbp polypeptides |
| WO2011057148A1 (en) | 2009-11-05 | 2011-05-12 | Irm Llc | Compounds and compositions as tlr-7 activity modulators |
| SG10201501980SA (en) | 2009-12-15 | 2015-05-28 | Novartis Ag | Homogeneous suspension of immunopotentiating compounds and uses thereof |
| CA2791697C (en) * | 2010-03-12 | 2019-08-13 | Research Corporation Technologies | Viable gram negative bacteria lacking outer membrane agonists of tlr4/md-2 |
| CN102802662A (zh) | 2010-03-18 | 2012-11-28 | 诺华有限公司 | 用于脑膜炎球菌血清组b的含佐剂疫苗 |
| AU2011232421B2 (en) | 2010-03-23 | 2015-08-13 | Novartis Ag | Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc. |
| BR112013005626B1 (pt) | 2010-09-10 | 2022-07-26 | Glaxosmithkline Biologicals Sa | Meningococo, processo para a preparação de uma cepa meningocócica, vesículas de membrana externa, composição farmacêutica imunogênica, e, uso de uma composição |
| EP2707009A1 (en) | 2011-05-12 | 2014-03-19 | Novartis AG | Antipyretics to enhance tolerability of vesicle-based vaccines |
| JP5957541B2 (ja) | 2012-02-02 | 2016-07-27 | ノバルティス アーゲー | 髄膜炎菌における増加したタンパク質発現のためのプロモータ |
| US9526776B2 (en) | 2012-09-06 | 2016-12-27 | Glaxosmithkline Biologicals Sa | Combination vaccines with serogroup B meningococcus and D/T/P |
| JP6786394B2 (ja) | 2014-02-28 | 2020-11-18 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 改変髄膜炎菌ｆＨｂｐポリペプチド |
| EP3749340A1 (en) * | 2018-02-06 | 2020-12-16 | Evelo Biosciences, Inc. | Compositions and methods for treating cancer and immune disorders using veillonella bacteria |
| WO2019169181A1 (en) * | 2018-02-28 | 2019-09-06 | Evelo Biosciences, Inc. | Compositions and methods for treating cancer using lactobacillus salivarius |
| WO2019169168A1 (en) * | 2018-02-28 | 2019-09-06 | Evelo Biosciences, Inc. | Compositions and methods for treating cancer using agathobaculum |
| EP3799884A1 (en) * | 2019-10-01 | 2021-04-07 | GlaxoSmithKline Biologicals S.A. | Immunogenic compositions |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8912330D0 (en) * | 1989-05-30 | 1989-07-12 | Wellcome Found | Live vaccines |
| DK0624376T3 (da) | 1993-05-13 | 2000-07-24 | American Cyanamid Co | Fremstilling og anvendelse af LOS-udtømte ydre membranproteiner af gram-negative cocci |
| US6887483B2 (en) | 1995-12-01 | 2005-05-03 | University Of Iowa Research Foundation | Non-toxic mutants of pathogenic gram-negative bacteria |
| WO1997025061A1 (en) * | 1996-01-09 | 1997-07-17 | Bristol-Myers Squibb Company | De-myristolated lipopolysaccharide of gram-negative bacteria |
-
1997
- 1997-08-21 EP EP97936881A patent/EP0991761B1/en not_active Expired - Lifetime
- 1997-08-21 DE DE69738472T patent/DE69738472T2/de not_active Expired - Lifetime
- 1997-08-21 PT PT97936881T patent/PT991761E/pt unknown
- 1997-08-21 CA CA2300854A patent/CA2300854C/en not_active Expired - Fee Related
- 1997-08-21 WO PCT/NL1997/000474 patent/WO1999010497A1/en not_active Ceased
- 1997-08-21 JP JP2000507805A patent/JP2001514001A/ja active Pending
- 1997-08-21 AT AT97936881T patent/ATE384130T1/de active
- 1997-08-21 DK DK97936881T patent/DK0991761T3/da active
- 1997-08-21 AU AU39540/97A patent/AU755462B2/en not_active Ceased
- 1997-08-21 US US09/486,073 patent/US7011836B1/en not_active Expired - Lifetime
- 1997-08-21 ES ES97936881T patent/ES2301181T3/es not_active Expired - Lifetime
-
2000
- 2000-02-17 NO NO20000774A patent/NO326858B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU3954097A (en) | 1999-03-16 |
| US7011836B1 (en) | 2006-03-14 |
| CA2300854A1 (en) | 1999-03-04 |
| CA2300854C (en) | 2011-04-05 |
| DE69738472D1 (de) | 2008-03-06 |
| WO1999010497A1 (en) | 1999-03-04 |
| AU755462B2 (en) | 2002-12-12 |
| EP0991761A1 (en) | 2000-04-12 |
| EP0991761B1 (en) | 2008-01-16 |
| DE69738472T2 (de) | 2009-01-02 |
| PT991761E (pt) | 2008-04-28 |
| ATE384130T1 (de) | 2008-02-15 |
| ES2301181T3 (es) | 2008-06-16 |
| JP2001514001A (ja) | 2001-09-11 |
| NO20000774L (no) | 2000-04-14 |
| NO326858B1 (no) | 2009-03-02 |
| NO20000774D0 (no) | 2000-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0991761T3 (da) | Hidtil ukendte mutaner af gramnegative mucosale bakterier og anvendelse deraf i vacciner | |
| ATE319476T1 (de) | Neuartige nicht pyrogene bakterienstämme und ihre verwendung | |
| CY1113032T1 (el) | Ετερολογη εκφραση πρωτεϊνων νειssεrια | |
| BRPI0315228A8 (pt) | Vacinas de polipeptídeo para ampla proteção contra linhagens meningocócicas hipervirulentas | |
| ATE190502T1 (de) | Herstellung und verwendungen von los-verminderten aussenmembran-proteinen von gram-negativen kokken | |
| AU7392296A (en) | Dendritic cell stimulatory factor | |
| HUP9901039A2 (hu) | Neisseria meningitidis B-csoportba tartozó külső-membrán-fehérjéjének (MB3) expressziója élesztőben, továbbá vakcinák | |
| BR0015961A (pt) | Antìgeno de neisseria de 85kda | |
| DK0807178T3 (da) | Mycobaktielle proteiner, mikroorganismer producerende samme og anvendelser af nævnte proteiner i vacciner og til påvisning af tuberkulose | |
| ATE189961T1 (de) | Impfstoff gegen mycobakterielle infektionen | |
| Agabian et al. | Caulobacter crescentus cell envelope: effect of growth conditions on murein and outer membrane protein composition | |
| Pendleton et al. | Purification and partial characterization of hemolysins from Bacillus thuringiensis | |
| DK1192242T3 (da) | Fremstilling af den lipiderede form af de peptidgylcan-associerede lipoproteiner af gramnegative bakterier | |
| DK0563256T3 (da) | Anvendelse af værtscelle-phospholipider til inhibering af bakteriekolonisering | |
| Pugsley et al. | Comparison of colicins B-K260 and D-CA23: purification and characterization of the colicins and examination of colicin immunity in the producing strains | |
| NO920849L (no) | Fremgangsmaate for fremstilling av l-lysin ved fermentasjon | |
| ATE14984T1 (de) | Verfahren zur herstellung eines biochemischen vakzins gegen salmonellenfieber. | |
| WO2021252236A3 (en) | Native cell membrane nanoparticle and methods of use thereof | |
| RU94044956A (ru) | Способ получения антигена для создания диагностикума из ацетонвысушенных клеток м. tuberculosis | |
| Kawaoka et al. | Identification of Yersinia enterocolitica O15 lipopolysaccharide as a rough antigen | |
| Mardones et al. | Methylation of ribosomal proteins in Bacillus subtilis | |
| CY1114285T1 (el) | Μεθοδοι για την παρασκευη 3-ο-αποακυλιωμενου-4’-μονοφωσφορυλο λιπιδιου α (3d-mla) | |
| HONG et al. | Production of ETAF from Human Epidermal Cells | |
| Hill | Restricted lateral diffusion of surface membrane components in Tetrahymena thermophila | |
| NO943251L (no) | Oral vaksine |